Clinical evaluation of DIAGNOVIR SARS-CoV-2 ultra-rapid antigen test performance compared to PCR-based testing
Ali Aytac Seymen
(EA Teknoloji LLC Bilkent CyberPark)
Ezgi Gulten
(Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University)
Erol Ozgur
(EA Teknoloji LLC Bilkent CyberPark)
Bülend Ortaç
(EA Teknoloji LLC Bilkent CyberPark)
Irem Akdemir
(Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University)
Gule Cinar
(Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University)
Elif Mukime Saricaoglu
(Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University)
Gulen Guney-Esken
(Koc University IsBank Research Center for Infectious Diseases (KUISCID))
Erman Akkus
(Department of Internal Medicine, Faculty of Medicine, Ankara University)
Fusun Can
(School of Medicine, Department of Medical Microbiology, Koc University)
Zeynep Ceren Karahan
(Department of Medical Microbiology, Faculty of Medicine, Ankara University)
Alpay Azap
(Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University)
Erkan Tuncay
(Departments of Biophysics, Faculty of Medicine, Ankara University)
Abstract Coronavirus Disease-19 (COVID-19) is a highly contagious infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The development of rapid antigen tests has contributed to easing the burden on healthcare and lifting restrictions by detecting infected individuals to help prevent further transmission of the virus. We developed a state-of-art rapid antigen testing system, named DIAGNOVIR, based on immune-fluorescence analysis, which can process and give the results in a minute. In our study, we assessed the performance of the DIAGNOVIR and compared the results with those of the qRT-PCR test. Our results demonstrated that the sensitivity and specificity of the DIAGNOVIR were 94% and 99.2%, respectively, with a 100% sensitivity and 96.97% specificity, among asymptomatic patients. In addition, DIAGNOVIR can detect SARS‑CoV‑2 with 100% sensitivity up to 5 days after symptom onset. We observed that the DIAGNOVIR Rapid Antigen Test’s limit of detection (LoD) was not significantly affected by the SARS‑CoV‑2 variants including Wuhan, alpha (B1.1.7), beta (B.1.351), delta (B.1.617.2) and omicron (B.1.1.529) variants, and LoD was calculated as 8 × 102, 6.81 × 101.5, 3.2 × 101.5, 1 × 103, and 1 × 103.5 TCID50/mL, respectively. Our results indicated that DIAGNOVIR can detect all SARS-CoV-2 variants in just seconds with higher sensitivity and specificity lower testing costs and decreased turnover time.